JP7661299B2 - Ｄｌｌ３をターゲッティングする抗体とその使用 - Google Patents

Ｄｌｌ３をターゲッティングする抗体とその使用 Download PDF

Info

Publication number
JP7661299B2
JP7661299B2 JP2022501134A JP2022501134A JP7661299B2 JP 7661299 B2 JP7661299 B2 JP 7661299B2 JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022501134 A JP2022501134 A JP 2022501134A JP 7661299 B2 JP7661299 B2 JP 7661299B2
Authority
JP
Japan
Prior art keywords
seq
dll3
antibody
sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022501134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540611A (ja
JP2022540611A5 (https=
Inventor
ジョン ティー ポワリエ
チャールズ ルディン
ジェイソン ルイス
アブドゥル カーン
デヴィッド アンドリュー
シンレイ チェン
イヴォ ロレンツ
Original Assignee
メモリアル スローン ケタリング キャンサー センター
ティーアールアイ－インスティテューショナル セラピューティクス ディスカバリー インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, ティーアールアイ－インスティテューショナル セラピューティクス ディスカバリー インスティテュート filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2022540611A publication Critical patent/JP2022540611A/ja
Publication of JP2022540611A5 publication Critical patent/JP2022540611A5/ja
Priority to JP2025061352A priority Critical patent/JP2025156278A/ja
Application granted granted Critical
Publication of JP7661299B2 publication Critical patent/JP7661299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022501134A 2019-07-11 2020-07-08 Ｄｌｌ３をターゲッティングする抗体とその使用 Active JP7661299B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061352A JP2025156278A (ja) 2019-07-11 2025-04-02 Ｄｌｌ３をターゲッティングする抗体とその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872915P 2019-07-11 2019-07-11
US62/872,915 2019-07-11
PCT/US2020/041282 WO2021007371A1 (en) 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061352A Division JP2025156278A (ja) 2019-07-11 2025-04-02 Ｄｌｌ３をターゲッティングする抗体とその使用

Publications (3)

Publication Number Publication Date
JP2022540611A JP2022540611A (ja) 2022-09-16
JP2022540611A5 JP2022540611A5 (https=) 2023-07-12
JP7661299B2 true JP7661299B2 (ja) 2025-04-14

Family

ID=74115317

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022501134A Active JP7661299B2 (ja) 2019-07-11 2020-07-08 Ｄｌｌ３をターゲッティングする抗体とその使用
JP2025061352A Pending JP2025156278A (ja) 2019-07-11 2025-04-02 Ｄｌｌ３をターゲッティングする抗体とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061352A Pending JP2025156278A (ja) 2019-07-11 2025-04-02 Ｄｌｌ３をターゲッティングする抗体とその使用

Country Status (13)

Country Link
US (1) US12441789B2 (https=)
EP (1) EP3997127A4 (https=)
JP (2) JP7661299B2 (https=)
KR (1) KR20220034167A (https=)
CN (3) CN119080930A (https=)
AU (1) AU2020310894A1 (https=)
BR (1) BR112022000216A2 (https=)
CA (1) CA3146566A1 (https=)
CO (1) CO2022001195A2 (https=)
IL (1) IL289585A (https=)
MX (1) MX2022000325A (https=)
PH (1) PH12022550056A1 (https=)
WO (1) WO2021007371A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025156278A (ja) * 2019-07-11 2025-10-14 メモリアル スローン ケタリング キャンサー センター Ｄｌｌ３をターゲッティングする抗体とその使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2718257T3 (https=) * 2014-05-30 2018-04-14
CA3204628A1 (en) * 2021-01-13 2022-07-21 John T. POIRIER Antibody-pyrrolobenzodiazepine derivative conjugate
MX2023008285A (es) * 2021-01-13 2023-09-12 Memorial Sloan Kettering Cancer Center Conjugado de anticuerpo anti-dll3-farmaco.
MX2023012614A (es) * 2021-05-08 2023-11-03 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd Molecula de union contra dll3 y uso de la misma.
AU2022339815A1 (en) * 2021-09-02 2024-03-14 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting dll3 and uses thereof
WO2023034557A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof
JP2024534892A (ja) * 2021-09-02 2024-09-26 メモリアル スローン ケタリング キャンサー センター 抗ｄｌｌ３抗体及びその使用
CA3240378A1 (en) * 2021-12-23 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody
EP4482859A1 (en) 2022-02-27 2025-01-01 Boehringer Ingelheim International GmbH Bispecific antibodies against cd277 and a tumor-antigen
CN116003628A (zh) * 2022-08-15 2023-04-25 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
WO2025184421A1 (en) * 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093097A1 (ja) 2010-01-29 2011-08-04 株式会社未来創薬研究所 抗dll3抗体
JP2015509947A (ja) 2012-02-24 2015-04-02 ステム セントリックス， インコーポレイテッド Ｄｌｌ３モジュレーター及び使用方法
JP2017514143A (ja) 2014-02-21 2017-06-01 アッヴィ・ステムセントルクス・エル・エル・シー メラノーマに使用するための抗ｄｌｌ３抗体および薬物コンジュゲート

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
AU2007325872B2 (en) * 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
WO2012013813A1 (en) 2010-07-30 2012-02-02 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
NZ626242A (en) * 2012-01-31 2017-02-24 Regeneron Pharma Anti-asic1 antibodies and uses thereof
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
PT3221356T (pt) 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
CN119080930A (zh) * 2019-07-11 2024-12-06 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093097A1 (ja) 2010-01-29 2011-08-04 株式会社未来創薬研究所 抗dll3抗体
JP2015509947A (ja) 2012-02-24 2015-04-02 ステム セントリックス， インコーポレイテッド Ｄｌｌ３モジュレーター及び使用方法
JP2017514143A (ja) 2014-02-21 2017-06-01 アッヴィ・ステムセントルクス・エル・エル・シー メラノーマに使用するための抗ｄｌｌ３抗体および薬物コンジュゲート

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sci Transl Med.，2015年，Vol.7, Issue 302，p.302ra136

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025156278A (ja) * 2019-07-11 2025-10-14 メモリアル スローン ケタリング キャンサー センター Ｄｌｌ３をターゲッティングする抗体とその使用

Also Published As

Publication number Publication date
CN114341182B (zh) 2024-09-10
JP2025156278A (ja) 2025-10-14
AU2020310894A1 (en) 2022-02-03
CA3146566A1 (en) 2021-01-14
JP2022540611A (ja) 2022-09-16
US20220348648A1 (en) 2022-11-03
EP3997127A1 (en) 2022-05-18
US12441789B2 (en) 2025-10-14
CN119080930A (zh) 2024-12-06
MX2022000325A (es) 2022-03-25
BR112022000216A2 (pt) 2022-05-17
CO2022001195A2 (es) 2022-03-08
KR20220034167A (ko) 2022-03-17
PH12022550056A1 (en) 2023-04-12
CN118955717A (zh) 2024-11-15
IL289585A (en) 2022-03-01
WO2021007371A1 (en) 2021-01-14
CN114341182A (zh) 2022-04-12
EP3997127A4 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
JP7661299B2 (ja) Ｄｌｌ３をターゲッティングする抗体とその使用
JP7791836B2 (ja) 抗ｃｄ３抗体及びその使用
JP7598324B2 (ja) Ｃｄ３３抗体とそれを用いた癌を治療する方法
US20240327511A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
US20240002501A1 (en) Anti-l1-cam antibodies and uses thereof
JP7805287B2 (ja) 抗ｓｔｅａｐ１抗体およびその使用
JP7730295B2 (ja) Ｃｄ１９抗体およびこれを使用する方法
JP7788859B2 (ja) がんを処置するための抗ｃｄ３３抗体
JP7386800B2 (ja) 抗ポリシアル酸抗体およびその使用
US20250340637A1 (en) Cd3 targeting antibodies and uses thereof
WO2024031009A2 (en) Anti-cd24 antibodies and uses thereof
RU2839959C2 (ru) Dll3-нацеливающие антитела и их применения
WO2022081443A2 (en) Anti-psma antibodies and uses thereof
WO2024226646A2 (en) Dlk1 -targeting antibodies and uses thereof
AU2024344464A1 (en) Gpa33 antibody compositions and uses thereof
EA046795B1 (ru) Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230704

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250402

R150 Certificate of patent or registration of utility model

Ref document number: 7661299

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150